Rancés Blanco, Yisel Quintana, Damián Blanco, Mercedes Cedeño, Charles E Rengifo, Milagros Frómeta, Martha Ríos, Enrique Rengifo, Adriana Carr
{"title":"14F7单抗在神经外胚层、中胚层和上皮源性肿瘤中对N-Glycolyl GM3神经节苷脂的组织反应性提高","authors":"Rancés Blanco, Yisel Quintana, Damián Blanco, Mercedes Cedeño, Charles E Rengifo, Milagros Frómeta, Martha Ríos, Enrique Rengifo, Adriana Carr","doi":"10.1155/2013/602417","DOIUrl":null,"url":null,"abstract":"<p><p>The expression of N-glycolylneuraminic acid forming the structure of gangliosides and/or other glycoconjugates (Hanganutziu-Deicher antigen) in human has been considered as a tumor-associated antigen. Specifically, some reports of 14F7 Mab (a highly specific Mab raised against N-glycolyl GM3 ganglioside) reactivity in human tumors have been recently published. Nevertheless, tumors of epithelial origin have been mostly evaluated. The goal of the present paper was to evaluate the immunohistochemical recognition of 14F7 Mab in different human tumors of neuroectodermal, mesodermal, and epithelial origins using an immunoperoxidase staining method. Samples of fetal, normal, and reactive astrocytosis of the brain were also included in the study. In general, nontumoral tissues, as well as, low-grade brain tumors showed no or a limited immunoreaction with 14F7 Mab. Nevertheless, high-grade astrocytomas (III-IV) and neuroblastomas, as well as, sarcomas and thyroid carcinomas were mostly reactive with 14F7. No reaction was evidenced in medulloblastomas and ependymoblastomas. Our data suggest that the expression of N-glycolyl GM3 ganglioside could be related to the aggressive behavior of malignant cells, without depending on the tumor origin. Our data could also support the possible use of N-glycolyl GM3 as a target for both active and passive immunotherapies of malignancies expressing this molecule. </p>","PeriodicalId":91105,"journal":{"name":"Journal of biomarkers","volume":"2013 ","pages":"602417"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/602417","citationCount":"20","resultStr":"{\"title\":\"Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin.\",\"authors\":\"Rancés Blanco, Yisel Quintana, Damián Blanco, Mercedes Cedeño, Charles E Rengifo, Milagros Frómeta, Martha Ríos, Enrique Rengifo, Adriana Carr\",\"doi\":\"10.1155/2013/602417\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The expression of N-glycolylneuraminic acid forming the structure of gangliosides and/or other glycoconjugates (Hanganutziu-Deicher antigen) in human has been considered as a tumor-associated antigen. Specifically, some reports of 14F7 Mab (a highly specific Mab raised against N-glycolyl GM3 ganglioside) reactivity in human tumors have been recently published. Nevertheless, tumors of epithelial origin have been mostly evaluated. The goal of the present paper was to evaluate the immunohistochemical recognition of 14F7 Mab in different human tumors of neuroectodermal, mesodermal, and epithelial origins using an immunoperoxidase staining method. Samples of fetal, normal, and reactive astrocytosis of the brain were also included in the study. In general, nontumoral tissues, as well as, low-grade brain tumors showed no or a limited immunoreaction with 14F7 Mab. Nevertheless, high-grade astrocytomas (III-IV) and neuroblastomas, as well as, sarcomas and thyroid carcinomas were mostly reactive with 14F7. No reaction was evidenced in medulloblastomas and ependymoblastomas. Our data suggest that the expression of N-glycolyl GM3 ganglioside could be related to the aggressive behavior of malignant cells, without depending on the tumor origin. Our data could also support the possible use of N-glycolyl GM3 as a target for both active and passive immunotherapies of malignancies expressing this molecule. </p>\",\"PeriodicalId\":91105,\"journal\":{\"name\":\"Journal of biomarkers\",\"volume\":\"2013 \",\"pages\":\"602417\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2013/602417\",\"citationCount\":\"20\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of biomarkers\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2013/602417\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2013/1/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomarkers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/602417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20
摘要
n -糖基神经氨酸在人体中的表达形成神经节苷脂和/或其他糖缀合物(Hanganutziu-Deicher抗原)的结构,被认为是肿瘤相关抗原。具体来说,最近发表了一些关于14F7 Mab(一种针对n -糖酰GM3神经节苷脂的高度特异性Mab)在人类肿瘤中的反应性的报道。然而,上皮来源的肿瘤大多被评估过。本论文的目的是利用免疫过氧化物酶染色法评估14F7单抗在不同神经外胚层、中胚层和上皮来源的人类肿瘤中的免疫组织化学识别。胎儿、正常和反应性脑星形细胞增多症的样本也包括在研究中。一般来说,非肿瘤组织以及低级别脑肿瘤对14F7 Mab没有或只有有限的免疫反应。然而,高级别星形细胞瘤(III-IV)和神经母细胞瘤,以及肉瘤和甲状腺癌大多对14F7有反应。髓母细胞瘤和室管膜母细胞瘤无反应。我们的数据表明,n -糖基GM3神经节苷脂的表达可能与恶性细胞的侵袭行为有关,而与肿瘤来源无关。我们的数据也可以支持n -糖酰GM3作为表达该分子的恶性肿瘤的主动和被动免疫治疗靶点的可能性。
Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin.
The expression of N-glycolylneuraminic acid forming the structure of gangliosides and/or other glycoconjugates (Hanganutziu-Deicher antigen) in human has been considered as a tumor-associated antigen. Specifically, some reports of 14F7 Mab (a highly specific Mab raised against N-glycolyl GM3 ganglioside) reactivity in human tumors have been recently published. Nevertheless, tumors of epithelial origin have been mostly evaluated. The goal of the present paper was to evaluate the immunohistochemical recognition of 14F7 Mab in different human tumors of neuroectodermal, mesodermal, and epithelial origins using an immunoperoxidase staining method. Samples of fetal, normal, and reactive astrocytosis of the brain were also included in the study. In general, nontumoral tissues, as well as, low-grade brain tumors showed no or a limited immunoreaction with 14F7 Mab. Nevertheless, high-grade astrocytomas (III-IV) and neuroblastomas, as well as, sarcomas and thyroid carcinomas were mostly reactive with 14F7. No reaction was evidenced in medulloblastomas and ependymoblastomas. Our data suggest that the expression of N-glycolyl GM3 ganglioside could be related to the aggressive behavior of malignant cells, without depending on the tumor origin. Our data could also support the possible use of N-glycolyl GM3 as a target for both active and passive immunotherapies of malignancies expressing this molecule.